Company
Headquarters: Chengdu, China
Employees: 408
CN¥8.46 Billion
CNY as of July 1, 2025
US$1.18 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥1.26 B |
| EBITDA | CN¥414.7 M |
| Gross Profit TTM | CN¥1.18 B |
| Profit Margin | 21.45% |
| Operating Margin | 13.74% |
| Quarterly Revenue Growth | -55.70% |
Chengdu Kanghua Biological Products Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300841 wb_incandescent